Anna‐Louise Funk

Anna‐Louise Funk

Auto-generated profile, based on publicly available information

Anna‐Louise Funk

Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary , Calgary, Alberta

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
MEMohamed El-Kassas
Mohamed El-Kassas
AFA. L. Funk
A. L. Funk
MSM. Salaheldin
M. Salaheldin
YSY. Shimakawa
Y. Shimakawa
MEM. Eltabbakh
M. Eltabbakh
AFA. Fontanet
A. Fontanet

22 May 2018 in Liver International
Verified
Journal Article
Closed access
PDF file
MEMohamed El-Kassas
Mohamed El-Kassas
yusuke shimakawayusuke shimakawa
yusuke shimakawa
ZAZainab Ali‐Eldin
Zainab Ali‐Eldin
AFAnna‐Louise Funk
Anna‐Louise Funk
MWMohamed Naguib Wifi
Mohamed Naguib Wifi
AFArnaud Fontanet
Arnaud Fontanet

15 January 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
AFAnna L. Funk
Anna L. Funk
TFTodd A. Florin
Todd A. Florin
SDStuart R. Dalziel
Stuart R. Dalziel
SMSantiago Mintegi
Santiago Mintegi
MSMarina I. Salvadori
Marina I. Salvadori
SFStephen Freedman
Stephen Freedman
Introduction Relatively limited data are available regarding paediatric COVID-19. Although most children appear to have mild or asymptomatic infections, infants and those with comorbidities are at increased risk of experiencing more severe illness and requiring hospitalisation due to COVID-19. The recent but uncommon association of SARS-CoV-2 infection with development of a multisystem inflammatory syndrome has heightened the importance of understanding paediatric SARS-CoV-2 infection. Methods and analysis The Paediatric Emergency Research Network-COVID-19 cohort study is a rapid, global, prospective cohort study enrolling 12 500 children who are tested for acute SARS-CoV-2 infection. 47 emergency departments across 12 countries on four continents will participate. At enrolment, regardless of SARS-CoV-2 test results, all children will have the same information collected, including clinical, epidemiological, laboratory, imaging and outcome data. Interventions and outcome data will be collected for hospitalised children. For all children, follow-up at 14 and 90 days will collect information on further medical care received, and long-term sequelae, respectively. Statistical models will be designed to identify risk factors for infection and severe outcomes. Ethics and dissemination Sites will seek ethical approval locally, and informed consent will be obtained. There is no direct risk or benefit of study participation. Weekly interim analysis will allow for real-time data sharing with regional, national, and international policy makers. Harmonisation and sharing of investigation materials with WHO, will contribute to synergising global efforts for the clinical characterisation of paediatric COVID-19. Our findings will enable the implementation of countermeasures to reduce viral transmission and severe COVID-19 outcomes in children. Trial registration number NCT04330261

26 March 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAnna Funk
Anna Funk
TFTodd A Florin
Todd A Florin
NKNathan Kuppermann
Nathan Kuppermann
YFYaron Finkelstein
Yaron Finkelstein
AKAlissa Kazakoff
Alissa Kazakoff
SFStephen Freedman
Stephen Freedman
Background: Asymptomatic SARS-CoV-2 infection in children is highly prevalent but its acute and chronic implications have been minimally described. Methods: In this controlled case-ascertained household transmission study, we recruited asymptomatic children <18 years with SARS-CoV-2 nucleic acid testing performed at 12 tertiary care pediatric institutions in Canada and the United States. We attempted to recruit all test-positive children and 1 to 3 test-negative, site-matched controls. After 14 days’ follow-up we assessed the clinical (ie, symptomatic) and combined (ie, test-positive, or symptomatic) secondary attack rates (SARs) among household contacts. Additionally, post–COVID-19 condition (PCC) was assessed in SARS-CoV-2–positive participating children after 90 days’ follow-up. Results: A total of 111 test-positive and 256 SARS-CoV-2 test-negative asymptomatic children were enrolled between January 2021 and April 2022. After 14 days, excluding households with co-primary cases, the clinical SAR among household contacts of SARS-CoV-2–positive and –negative index children was 10.6% (19/179; 95% CI: 6.5%–16.1%) and 2.0% (13/663; 95% CI: 1.0%–3.3%), respectively (relative risk = 5.4; 95% CI: 2.7–10.7). In households with a SARS-CoV-2–positive index child, age <5 years, being pre-symptomatic (ie, developed symptoms after test), and testing positive during Omicron and Delta circulation periods (vs earlier) were associated with increased clinical and combined SARs among household contacts. Among 77 asymptomatic SARS-CoV-2–infected children with 90-day follow-up, 6 (7.8%; 95% CI: 2.9%–16.2%) reported PCC. Conclusions: Asymptomatic SARS-CoV-2–infected children, especially those <5 years, are important contributors to household transmission, with 1 in 10 exposed household contacts developing symptomatic illness within 14 days. Asymptomatic SARS-CoV-2–infected children may develop PCC.

10 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
RGRebecca Grant
Rebecca Grant
OFOlivier FLECHELLES
Olivier FLECHELLES
Narcisse ELENGANarcisse ELENGA
Narcisse ELENGA
BTBenoît Tressières
Benoît Tressières
SGStanie GAETE
Stanie GAETE
BHBruno Hoen
Bruno Hoen
We aimed to describe adverse pregnancy outcomes among women who had symptomatic, RT-PCR-confirmed ZIKV infection and early childhood outcomes among their infants. We enrolled pregnant women with symptomatic, RT-PCR-confirmed ZIKV infection in a prospective cohort study, and their infants in a prospective pediatric cohort study. We defined adverse pregnancy and early childhood outcomes based on selected neurologic, ophthalmologic, auditory, musculoskeletal, and anthropometric abnormalities. We used RT-PCR and serologic tests to determine the ZIKV infection status of the child. Between 10 March and 24 November 2016, we enrolled 546 pregnant women with RT-PCR-confirmed ZIKV infection. The overall risk of adverse pregnancy and early childhood outcomes possibly related to in utero ZIKV exposure was 15.7% (95% CI: 12.8–19.0), distributed as follows: 3.6% (95% CI: 2.3–5.6) severe sequelae or fatality; 2.7% (95% CI: 1.6–4.5) major abnormalities; 9.4% (95% CI:7.1–12.2) mild abnormalities. The risk of severe sequelae or fatality was higher when ZIKV infection occurred during the first trimester (7.0%), compared to the second (2.7%) or third trimester (1.4%) (p = 0.02). Among the infants for whom ZIKV infection status could be determined, the vertical transmission rate was 3.0% (5/167) (95% CI: 1.1–7.2). Among pregnant women with symptomatic, RT-PCR-confirmed ZIKV infection, severe or major pregnancy or early childhood outcomes were present in 6.3% of fetuses and infants. Severe outcomes occurred more frequently in fetuses and infants whose mothers had been infected in the first trimester.

3 March 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AFAnna L. Funk
Anna L. Funk
BHBruno Hoen
Bruno Hoen
IVIngrid Vingdassalom
Ingrid Vingdassalom
CRCatherine Ryan
Catherine Ryan
PKPhilippe Kadhel
Philippe Kadhel
AFArnaud Fontanet
Arnaud Fontanet
In the French Territories in the Americas (FTA), the risk of birth defects possibly associated with Zika virus (ZIKV) infection was 7.0% (95%CI: 5.0 to 9.5) among foetuses/infants of 546 women with symptomatic RT-PCR confirmed ZIKV infection during pregnancy. Many of these defects were isolated measurement-based microcephaly (i.e. without any detected brain or clinical abnormalities) or mild neurological conditions. We wanted to estimate the proportion of such minor findings among live births of women who were pregnant in the same region during the outbreak period but who were not infected with ZIKV. In Guadeloupe, pregnant women were recruited at the time of delivery and tested for ZIKV infection. The outcomes of live born infants of ZIKV non-infected women were compared to those of ZIKV-exposed live born infants in Guadeloupe, extracted from the FTA prospective cohort. Of 490 live born infants without exposure to ZIKV, 42 infants (8.6%, 95%CI: 6.2–11.4) had mild abnormalities that have been described as ‘potentially linked to ZIKV infection’; all but one of these was isolated measurement-based microcephaly. Among the 241 live born infants with ZIKV exposure, the proportion of such abnormalities, using the same definition, was similar (6.6%, 95%CI: 3.8–10.6). Isolated anthropometric abnormalities and mild neurological conditions were as prevalent among infants with and without in-utero ZIKV exposure. If such abnormalities had not been considered as ‘potentially linked to ZIKV’ in the original prospective cohort in Guadeloupe, the overall estimate of the risk of birth defects considered due to the virus would have been significantly lower, at approximately 1.6% (95% CI: 0.4–4.1). ClinicalTrials.gov (NCT02916732) Microcephaly defined using growth charts occurs naturally in some healthy infants. Nonetheless, in many recent Zika virus studies, such measurement-based microcephaly and other common mild abnormalities have been automatically attributed to viral exposure during pregnancy. For example, in 2016 in Guadeloupe, we did a cohort study and estimated that the risk of Zika virus related birth defects was 7%. However, most of the ‘abnormal’ live born infants that contributed to this risk estimate were considered healthy by pediatricians, but were found to have measurement-based microcephaly during data analysis. In the current study, we did a cross-sectional evaluation of infants live born in 2016 in Guadeloupe, but whose mothers were not infected with Zika virus during pregnancy. We found that Zika virus unexposed live born infants had similar proportions of measurement-based microcephaly and mild neurological abnormalities as exposed live born infants. If only severe and uncommon birth defects were considered linked to Zika virus in our original cohort study, our risk estimate would have been significantly lower. This research shows that it is important to consider baseline risks and control comparisons when establishing key parameters for emerging diseases, such as Zika virus.